Clinical

Dataset Information

0

Investigation of the blood levels at a reduced dose of erlotinib with the addition of ritonavir compared to the normal dose of erlotinib


ABSTRACT: Primary objectives: Effect of the highly potent CYP3A4 inhibitor ritonavir on the pharmacokinetics (PK) of erlotinib, measured as AUC0-24h, AUCmean, Cmax and Cmin Primary endpoints: The effect of the highly potent CYP3A4 inhibitor ritonavir on the pharmacokinetics (PK) of erlotinib, measured as AUC0-24h, Cmax and Cmin.

DISEASE(S): Non-small Cell Lung Cancer Stage Iv,Advanced Egfr Mutation Positive Non Small Cell Lung Cancer, Pancreatic Carcinoma, Colorectal Cancer And Biliary Cancer,Gevorderd Egfr Mutatie Positief Niet-kleincellig Longkanker, Pancreascarcinoom, Colorectaal Kanker En Galwegkanker

PROVIDER: 2538815 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2014-10-07 | E-GEOD-62118 | biostudies-arrayexpress
2014-10-07 | GSE62118 | GEO
2019-01-01 | GSE106151 | GEO
2017-10-26 | GSE67545 | GEO
2020-12-19 | GSE148465 | GEO
2015-09-15 | E-MTAB-3391 | biostudies-arrayexpress
2015-09-15 | E-MTAB-3387 | biostudies-arrayexpress
2015-02-25 | E-GEOD-51212 | biostudies-arrayexpress
2014-06-19 | GSE57422 | GEO
2017-09-23 | GSE80344 | GEO